Diurnal is committed to transparency in its interactions. Diurnal commits to following the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry, which has clear requirements for working with healthcare professionals and healthcare organisations. Diurnal has published details of its transfers of value to healthcare organisations in via the ABPI website and below. Diurnal has gone beyond the requirements of the ABPI code by publishing all of its transfers of value worldwide.

Diurnal also complies with the EFPIA through this route. Where individual countries have other transparency regulations, Diurnal's declarations for these can be found below.

Diurnal is committed to transparency in clinical trials and publishes the protocols and results of its clinical trials on the website  www.clinicaltrials.gov

Diurnal Methodology - 2019

ABPI UK Disclosure - Report 2019 

Diurnal Methodology - 2018

ABPI UK Disclosure - Report 2018 

Diurnal Methodology - 2017

ABPI UK Disclosure - Report 2017

Diurnal Methodology - 2016

ABPI UK Disclosure - Report 2016

Diurnal Grants and Donations - 2016

Diurnal Methodology - 2015 

ABPI UK Disclosure – Report 2015